1. Medication adherence in schizophrenia: Factors influencing adherence and consequences of nonadherence, a systematic literature review;Higashi;Ther Adv Psychopharmacol,2013
2. Do psychiatric patients take their drugs?;Wilcox;BMJ,1965
3. The expert consensus guideline series: Adherence problems in patients with serious and persistent mental illness;Velligan;J Clin Psychiatry,2009
4. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: Clinical studies;Kane;J Clin Psychiatry,2003
5. Janssen Announces US FDA Approval of Invega Hafyera (6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia. News Release. Johnson & Johnson; September 01, 2021. Available from: https://www.jnj.com/janssen-announces-u-s-fda-approval-of-invega-hafyera-6-month-paliperidone-palmitate-first-and-only-twice-yearly-treatment-for-adults-with-schizophrenia. [Last accessed on 2022 Jan 29].